Document is current
Any future updates will be listed below
-
Authors
Welch, Baustin M.
Parikh, Sameer A. https://orcid.org/0000-0002-3221-7314
Kay, Neil E. https://orcid.org/0000-0002-5951-5055
Medina, Kay L. https://orcid.org/0000-0003-4188-8053
- License Information
-
More Information
Article History
Received: 21 August 2024
Revised: 25 February 2025
Accepted: 19 March 2025
First Online: 26 June 2025
Competing interests
: Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which SAP is a principal investigator. Honoraria has been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Janssen, Genentech, Amgen, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie for SAP’s participation in consulting activities/advisory board meetings. Research funding to NEK has been provided by Acerta Pharma BV, Celgene, Genentech, Pharmacyclics, and Tolero Pharmaceutical. NEK also participates in the data safety monitoring committees of Agios Pharm, AstraZeneca, Celgene, Cytomx Therapeutics, Genentech, Infinity Pharm, Morpho-Sys, and Pharmacyclics (he is not personally compensated for his participation). All other authors declare no competing interests.
